Get the Stockscreener App
25.12
2.37%
-0.61
Pre-market:
24.95
-0.17
-0.68%
Apellis Pharmaceuticals Inc stock is traded at $25.12, with a volume of 1.33M.
It is down -2.37% in the last 24 hours and down -3.53% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$25.73
Open:
$25.99
24h Volume:
1.33M
Relative Volume:
0.55
Market Cap:
$3.17B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-12.37
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+5.55%
1M Performance:
-3.53%
6M Performance:
+33.69%
1Y Performance:
-5.81%
1-Day Range:
$24.74
$25.99
1-Week Range:
$23.34
$26.37
52-Week Range:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
25.12 | 3.25B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
How to integrate Apellis Pharmaceuticals Inc. into portfolio analysis tools2025 Retail Activity & Daily Momentum Trading Reports - newser.com
How to forecast Apellis Pharmaceuticals Inc. trends using time seriesWeekly Profit Summary & Stepwise Trade Execution Plans - newser.com
What analysts say about Apellis Pharmaceuticals Inc stockVWAP Trading Strategies & Master Stock Selection - earlytimes.in
Price momentum metrics for Apellis Pharmaceuticals Inc. explainedQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
Using Bollinger Bands to evaluate Apellis Pharmaceuticals Inc.Quarterly Portfolio Summary & Growth Oriented Trading Recommendations - newser.com
Identifying reversal signals in Apellis Pharmaceuticals Inc.2025 Performance Recap & AI Driven Stock Reports - newser.com
How to monitor Apellis Pharmaceuticals Inc. with trend dashboardsJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Why retail investors pile into Apellis Pharmaceuticals Inc. stock2025 Support & Resistance & Momentum Based Trading Signals - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Using data tools to time your Apellis Pharmaceuticals Inc. exitJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Key resistance and support levels for Apellis Pharmaceuticals Inc.July 2025 Fed Impact & AI Based Buy and Sell Signals - newser.com
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Raises Target Price to $28 - 富途牛牛
Can Apellis Pharmaceuticals Inc. stock surprise with earnings upside2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com
Fierce Biotech Layoff Tracker 2025: Pharming cuts staff in restructuring; Bolt halves headcount - Fierce Biotech
Published on: 2025-10-05 07:38:09 - newser.com
Volume spikes in Apellis Pharmaceuticals Inc. stock – what they meanJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Can Apellis Pharmaceuticals Inc. (1JK) stock sustain institutional flows2025 Price Momentum & Smart Money Movement Tracker - newser.com
Using R and stats models for Apellis Pharmaceuticals Inc. forecastingJuly 2025 Recap & Fast Entry Momentum Alerts - newser.com
Smart tools for monitoring Apellis Pharmaceuticals Inc.’s price action2025 Market Outlook & Verified Swing Trading Watchlist - newser.com
Candlestick signals on Apellis Pharmaceuticals Inc. stock todayWeekly Trade Analysis & Accurate Buy Signal Alerts - newser.com
J. Safra Sarasin Holding AG Buys 68,588 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS) - MSN
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Complement 3 Glomerulopathy Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | ChemoCentryx, Novartis, Omeros Corporation, Apellis Pharma - Barchart.com
What Fibonacci levels say about Apellis Pharmaceuticals Inc. reboundTrade Signal Summary & Entry Point Strategy Guides - newser.com
What MACD and RSI say about Apellis Pharmaceuticals Inc.2025 Institutional Moves & Long Hold Capital Preservation Plans - newser.com
HC Wainwright Brokers Lower Earnings Estimates for APLS - MarketBeat
Apellis Pharmaceuticals: Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders - Seeking Alpha
Apellis Pharmaceuticals CFO Timothy Sullivan sells $51,827 in stock - MSN
What drives Apellis Pharmaceuticals Inc stock priceInstitutional Buying Trends & Free Exceptional Risk Adjusted Gains - earlytimes.in
H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals CFO sells $16,119 in stock - MSN
Published on: 2025-09-29 15:38:29 - newser.com
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apellis Pharmaceuticals Inc Stock (APLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dunlop A. Sinclair | Director |
Sep 19 '25 |
Sale |
22.95 |
31,092 |
713,561 |
68,908 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):